Rugino T A, Copley T C
Department of Pediatrics, Helping Hands Development Center, Marshall University School of Medicine, Huntington, WV, USA.
J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):230-5. doi: 10.1097/00004583-200102000-00018.
To examine the effect of once-daily dosing of modafinil, a stimulant that has a long duration of action, on clinical features of attention-deficit/hyperactivity disorder (ADHD) in children.
An open-label design was used to compare the Conners Parent and Teacher Rating Scale-Revised (L) (CPRS, CTRS), the ADHD Rating Scale-IV, and the Test of Variables of Attention (TOVA), without and with medication, in children with ADHD. Eleven children with ADHD, ranging in age from 5 to 15 years, took modafinil for an average of 4.6 weeks.
Average TOVA ADHD scores improved by 2.43 SD (p = .0009). CTRS and CPRS ADHD index T scores improved by an average of 14.1 (p = .0009) and 17.7 points (p = .001), respectively. The mean ADHD Rating Scale-IV scores improved from the 88th percentile to the 75th percentile (p = .047). One subject withdrew from the study because of an adverse event that was resolved completely with medication withdrawal. Other side effects were mild and responded to dose adjustment. No subjects required more than one dose per day.
Modafinil may be a useful once-daily treatment for children with ADHD. Further study using a double-blind, placebo-controlled design is needed.
研究每日一次服用莫达非尼（一种作用时间较长的兴奋剂）对儿童注意力缺陷多动障碍（ADHD）临床特征的影响。
采用开放标签设计，对ADHD儿童在未用药和用药情况下的Conners父母与教师评定量表修订版（L）（CPRS、CTRS）、ADHD评定量表-IV以及注意力变量测试（TOVA）进行比较。11名年龄在5至15岁的ADHD儿童服用莫达非尼，平均服用4.6周。
TOVA ADHD平均得分提高了2.43标准差（p = .0009）。CTRS和CPRS ADHD指数T得分分别平均提高了14.1（p = .0009）和17.7分（p = .001）。ADHD评定量表-IV的平均得分从第88百分位提高到了第75百分位（p = .047）。一名受试者因不良事件退出研究，停药后该事件完全得到解决。其他副作用较轻，通过调整剂量得到缓解。没有受试者需要每天服用超过一剂药物。
莫达非尼可能是一种对ADHD儿童有效的每日一次治疗药物。需要采用双盲、安慰剂对照设计进行进一步研究。
